Literature DB >> 34554848

Reply to T. Shimoi et al and Y. Shimanuki et al.

Ingrid A Mayer1, Fengmin Zhao1, Carlos L Arteaga1, William F Symmans1, Ben H Park1, Brian L Burnette1, Amye J Tevaarwerk1, Sofia F Garcia1, Karen L Smith1, Della F Makower1, Margaret Block1, Kimberly A Morley1, Chirag R Jani1, Craig Mescher1, Shabana J Dewani1, Bernard Tawfik1, Lisa E Flaum1, Erica L Mayer1, William M Sikov1, Eve T Rodler1, Lynne I Wagner1, Angela M DeMichele1, Joseph A Sparano1, Antonio C Wolff1, Kathy D Miller1.   

Abstract

Entities:  

Year:  2021        PMID: 34554848      PMCID: PMC8547907          DOI: 10.1200/JCO.21.01905

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

Review 1.  Breast Cancer Disparities: How Can We Leverage Genomics to Improve Outcomes?

Authors:  Melissa B Davis; Lisa A Newman
Journal:  Surg Oncol Clin N Am       Date:  2018-01       Impact factor: 3.495

Review 2.  Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.

Authors:  Brian D Lehmann; Jennifer A Pietenpol
Journal:  J Pathol       Date:  2014-01       Impact factor: 7.996

3.  Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.

Authors:  Tatsunori Shimoi; Emi Noguchi; Kazuki Sudo; Yu Jo Chua; Kan Yonemori
Journal:  J Clin Oncol       Date:  2021-09-23       Impact factor: 44.544

4.  Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?

Authors:  Yumiko Shimanuki; Akihiko Shimomura; Kenichi Yoshimura; Hiroyuki Terakado; Chikako Shimizu
Journal:  J Clin Oncol       Date:  2021-09-23       Impact factor: 44.544

5.  Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

Authors:  Norikazu Masuda; Soo-Jung Lee; Shoichiro Ohtani; Young-Hyuck Im; Eun-Sook Lee; Isao Yokota; Katsumasa Kuroi; Seock-Ah Im; Byeong-Woo Park; Sung-Bae Kim; Yasuhiro Yanagita; Shinji Ohno; Shintaro Takao; Kenjiro Aogi; Hiroji Iwata; Joon Jeong; Aeree Kim; Kyong-Hwa Park; Hironobu Sasano; Yasuo Ohashi; Masakazu Toi
Journal:  N Engl J Med       Date:  2017-06-01       Impact factor: 91.245

6.  Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

Authors:  Andrew N J Tutt; Judy E Garber; Bella Kaufman; Giuseppe Viale; Debora Fumagalli; Priya Rastogi; Richard D Gelber; Evandro de Azambuja; Anitra Fielding; Judith Balmaña; Susan M Domchek; Karen A Gelmon; Simon J Hollingsworth; Larissa A Korde; Barbro Linderholm; Hanna Bandos; Elżbieta Senkus; Jennifer M Suga; Zhimin Shao; Andrew W Pippas; Zbigniew Nowecki; Tomasz Huzarski; Patricia A Ganz; Peter C Lucas; Nigel Baker; Sibylle Loibl; Robin McConnell; Martine Piccart; Rita Schmutzler; Guenther G Steger; Joseph P Costantino; Amal Arahmani; Norman Wolmark; Eleanor McFadden; Vassiliki Karantza; Sunil R Lakhani; Greg Yothers; Christine Campbell; Charles E Geyer
Journal:  N Engl J Med       Date:  2021-06-03       Impact factor: 176.079

7.  Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.

Authors:  Ingrid A Mayer; Fengmin Zhao; Carlos L Arteaga; William F Symmans; Ben H Park; Brian L Burnette; Amye J Tevaarwerk; Sofia F Garcia; Karen L Smith; Della F Makower; Margaret Block; Kimberly A Morley; Chirag R Jani; Craig Mescher; Shabana J Dewani; Bernard Tawfik; Lisa E Flaum; Erica L Mayer; William M Sikov; Eve T Rodler; Lynne I Wagner; Angela M DeMichele; Joseph A Sparano; Antonio C Wolff; Kathy D Miller
Journal:  J Clin Oncol       Date:  2021-06-06       Impact factor: 50.717

  7 in total
  2 in total

1.  Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer.

Authors:  Julia E McGuinness; Vicky Ro; Simukayi Mutasa; Samuel Pan; Jianhua Hu; Meghna S Trivedi; Melissa K Accordino; Kevin Kalinsky; Dawn L Hershman; Richard S Ha; Katherine D Crew
Journal:  Breast Cancer Res Treat       Date:  2022-05-16       Impact factor: 4.872

Review 2.  EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.

Authors:  Alex Friedlaender; Vivek Subbiah; Alessandro Russo; Giuseppe Luigi Banna; Umberto Malapelle; Christian Rolfo; Alfredo Addeo
Journal:  Nat Rev Clin Oncol       Date:  2021-09-24       Impact factor: 66.675

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.